S&P 500   3,296.20 (+0.77%)
DOW   26,649.90 (+0.84%)
QQQ   269.41 (+1.36%)
AAPL   436.00 (+2.58%)
MSFT   214.37 (+4.57%)
FB   253.39 (-0.11%)
GOOGL   1,475.48 (-0.84%)
AMZN   3,123.02 (-1.32%)
NVDA   442.50 (+4.22%)
CGC   18.39 (+0.60%)
BABA   257.03 (+2.39%)
TSLA   1,498.50 (+4.73%)
MU   50.44 (+0.76%)
GE   6.16 (+1.48%)
AMD   78.01 (+0.75%)
T   29.50 (-0.27%)
F   6.68 (+1.06%)
ACB   10.12 (-0.69%)
GILD   71.83 (+3.31%)
NFLX   502.56 (+2.80%)
DIS   116.13 (-0.69%)
BAC   25.10 (+0.88%)
BA   162.89 (+3.09%)
S&P 500   3,296.20 (+0.77%)
DOW   26,649.90 (+0.84%)
QQQ   269.41 (+1.36%)
AAPL   436.00 (+2.58%)
MSFT   214.37 (+4.57%)
FB   253.39 (-0.11%)
GOOGL   1,475.48 (-0.84%)
AMZN   3,123.02 (-1.32%)
NVDA   442.50 (+4.22%)
CGC   18.39 (+0.60%)
BABA   257.03 (+2.39%)
TSLA   1,498.50 (+4.73%)
MU   50.44 (+0.76%)
GE   6.16 (+1.48%)
AMD   78.01 (+0.75%)
T   29.50 (-0.27%)
F   6.68 (+1.06%)
ACB   10.12 (-0.69%)
GILD   71.83 (+3.31%)
NFLX   502.56 (+2.80%)
DIS   116.13 (-0.69%)
BAC   25.10 (+0.88%)
BA   162.89 (+3.09%)
S&P 500   3,296.20 (+0.77%)
DOW   26,649.90 (+0.84%)
QQQ   269.41 (+1.36%)
AAPL   436.00 (+2.58%)
MSFT   214.37 (+4.57%)
FB   253.39 (-0.11%)
GOOGL   1,475.48 (-0.84%)
AMZN   3,123.02 (-1.32%)
NVDA   442.50 (+4.22%)
CGC   18.39 (+0.60%)
BABA   257.03 (+2.39%)
TSLA   1,498.50 (+4.73%)
MU   50.44 (+0.76%)
GE   6.16 (+1.48%)
AMD   78.01 (+0.75%)
T   29.50 (-0.27%)
F   6.68 (+1.06%)
ACB   10.12 (-0.69%)
GILD   71.83 (+3.31%)
NFLX   502.56 (+2.80%)
DIS   116.13 (-0.69%)
BAC   25.10 (+0.88%)
BA   162.89 (+3.09%)
S&P 500   3,296.20 (+0.77%)
DOW   26,649.90 (+0.84%)
QQQ   269.41 (+1.36%)
AAPL   436.00 (+2.58%)
MSFT   214.37 (+4.57%)
FB   253.39 (-0.11%)
GOOGL   1,475.48 (-0.84%)
AMZN   3,123.02 (-1.32%)
NVDA   442.50 (+4.22%)
CGC   18.39 (+0.60%)
BABA   257.03 (+2.39%)
TSLA   1,498.50 (+4.73%)
MU   50.44 (+0.76%)
GE   6.16 (+1.48%)
AMD   78.01 (+0.75%)
T   29.50 (-0.27%)
F   6.68 (+1.06%)
ACB   10.12 (-0.69%)
GILD   71.83 (+3.31%)
NFLX   502.56 (+2.80%)
DIS   116.13 (-0.69%)
BAC   25.10 (+0.88%)
BA   162.89 (+3.09%)
Log in

NASDAQ:LJPCLa Jolla Pharmaceutical Stock Price, Forecast & News

$4.10
+0.12 (+3.02 %)
(As of 08/3/2020 01:50 PM ET)
Add
Compare
Today's Range
$4.00
Now: $4.10
$4.16
50-Day Range
$3.89
MA: $4.63
$5.64
52-Week Range
$2.30
Now: $4.10
$11.41
Volume20,309 shs
Average Volume427,255 shs
Market Capitalization$111.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.
Read More
La Jolla Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.10 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.05 million
Book Value($2.21) per share

Profitability

Net Income$-116,510,000.00
Net Margins-355.86%

Miscellaneous

Employees169
Market Cap$111.93 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable
$4.10
+0.12 (+3.02 %)
(As of 08/3/2020 01:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

How has La Jolla Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

La Jolla Pharmaceutical's stock was trading at $4.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LJPC stock has decreased by 14.8% and is now trading at $4.10.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of La Jolla Pharmaceutical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for La Jolla Pharmaceutical
.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for La Jolla Pharmaceutical
.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.92) by $0.60. The biopharmaceutical company earned $7.59 million during the quarter, compared to analyst estimates of $8.50 million.
View La Jolla Pharmaceutical's earnings history
.

What price target have analysts set for LJPC?

4 brokerages have issued 1-year target prices for La Jolla Pharmaceutical's shares. Their forecasts range from $8.00 to $19.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $13.50 in the next year. This suggests a possible upside of 229.3% from the stock's current price.
View analysts' price targets for La Jolla Pharmaceutical
.

Has La Jolla Pharmaceutical been receiving favorable news coverage?

Media headlines about LJPC stock have been trending negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about La Jolla Pharmaceutical
.

Who are some of La Jolla Pharmaceutical's key competitors?

What other stocks do shareholders of La Jolla Pharmaceutical own?

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the following people:
  • Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
  • Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
  • Mr. James M. Rolke, Chief Scientific Officer (Age 50)
  • Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dupont Capital Management Corp (0.17%), Hollencrest Capital Management (0.10%), Signaturefd LLC (0.08%), UBS Group AG (0.07%) and Wedbush Securities Inc. (0.05%). Company insiders that own La Jolla Pharmaceutical stock include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla and Life Sciences Maste Perceptive.
View institutional ownership trends for La Jolla Pharmaceutical
.

Which major investors are selling La Jolla Pharmaceutical stock?

LJPC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for La Jolla Pharmaceutical
.

Which major investors are buying La Jolla Pharmaceutical stock?

LJPC stock was purchased by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, Signaturefd LLC, Hollencrest Capital Management, and Wedbush Securities Inc.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Darryl Wellinghoff, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, and Lakhmir S Chawla.
View insider buying and selling activity for La Jolla Pharmaceutical
.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $4.10.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $111.93 million and generates $23.05 million in revenue each year. The biopharmaceutical company earns $-116,510,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. La Jolla Pharmaceutical employs 169 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.